Compare Ginkgo Bioworks Holdings Inc (DNA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Msci Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.05 (market cap $763.64M), while Msci Inc trades at $563.48 (market cap $40.38B). The key difference: Msci Inc is far larger — about 52.9× Ginkgo Bioworks Holdings Inc's market cap, and Msci Inc pays a 1.48% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Msci Inc for 82 Days on average.
| DNA | MSCI | |
|---|---|---|
Market Cap | $763.64M | $40.38B |
Volume | 3,204,177 | 414,140 |
Sector | Health | Financials |
52-Week High | $15.83 | $643.83 |
52-Week Low | $5.48 | $511.84 |
Typical Hold Time | 7 Days | 82 Days |
Enterprise Value | $865.59M | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
MSCI trades at $563.55, up 1.47% today, with a bullish technical signal and strong fundamentals including 40.73% net income margin and consistent revenue growth. Recent news highlights the completion of the First Street acquisition and upcoming Q3 2026 earnings call, reinforcing its strategic expansion in climate risk analytics.
The outlook is positive with a consensus price target of $701.71, though high valuation ratios and a recent earnings miss pose risks. Long-term growth is supported by recurring revenue streams and market leadership in index and analytics services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
